|
Real-world treatment patterns and clinical outcomes of advanced melanoma patients following disease progression on anti-PD-1-based therapy. |
|
Leonel Fernando Hernandez-Aya |
Consulting or Advisory Role - Massive Bio |
Speakers' Bureau - Sanofi/Regeneron |
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Corvus Pharmaceuticals (Inst); Immunocore (Inst); MedImmune (Inst); Merck (Inst); Merck Serono (Inst); Polynoma (Inst); Regeneron (Inst); Roche/Genentech (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Sanofi/Regeneron |
|
|
No Relationships to Disclose |
|
|
|
|
|
No Relationships to Disclose |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
|
|
|
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
Employment - Bristol-Myers Squibb |
Stock and Other Ownership Interests - Bristol-Myers Squibb |